JP2011507972A5 - - Google Patents

Info

Publication number

JP2011507972A5

JP2011507972A5 JP2010540953A JP2010540953A JP2011507972A5 JP 2011507972 A5 JP2011507972 A5 JP 2011507972A5 JP 2010540953 A JP2010540953 A JP 2010540953A JP 2010540953 A JP2010540953 A JP 2010540953A JP 2011507972 A5 JP2011507972 A5 JP 2011507972A5

Authority

JP

Japan

Prior art keywords

peptide

virus

helix

amino acid

carbon

Prior art date

2008-12-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims 32
• 150000001413 amino acids Chemical group 0.000 claims 17
• 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 9
• 125000000217 alkyl group Chemical group 0.000 claims 9
• 125000003118 aryl group Chemical group 0.000 claims 9
• 238000000034 method Methods 0.000 claims 8
• VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims 7
• 108010075254 C-Peptide Proteins 0.000 claims 7
• 241000700605 Viruses Species 0.000 claims 7
• 208000036142 Viral infection Diseases 0.000 claims 6
• 230000009385 viral infection Effects 0.000 claims 6
• 241000725303 Human immunodeficiency virus Species 0.000 claims 4
• 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 4
• 229910052739 hydrogen Inorganic materials 0.000 claims 4
• 239000001257 hydrogen Substances 0.000 claims 4
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
• 239000003112 inhibitor Substances 0.000 claims 3
• 241000711573 Coronaviridae Species 0.000 claims 2
• 238000010485 C−C bond formation reaction Methods 0.000 claims 2
• 241001115402 Ebolavirus Species 0.000 claims 2
• 241000711950 Filoviridae Species 0.000 claims 2
• 241000700586 Herpesviridae Species 0.000 claims 2
• 241000282414 Homo sapiens Species 0.000 claims 2
• 241000701024 Human betaherpesvirus 5 Species 0.000 claims 2
• 241001559185 Mammalian rubulavirus 5 Species 0.000 claims 2
• 241000711466 Murine hepatitis virus Species 0.000 claims 2
• 241000712464 Orthomyxoviridae Species 0.000 claims 2
• 241000711504 Paramyxoviridae Species 0.000 claims 2
• 241000725643 Respiratory syncytial virus Species 0.000 claims 2
• 241000712907 Retroviridae Species 0.000 claims 2
• 241000315672 SARS coronavirus Species 0.000 claims 2
• 241000713311 Simian immunodeficiency virus Species 0.000 claims 2
• 208000000389 T-cell leukemia Diseases 0.000 claims 2
• 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 claims 2
• 238000003556 assay Methods 0.000 claims 2
• 230000002209 hydrophobic effect Effects 0.000 claims 2
• 238000005649 metathesis reaction Methods 0.000 claims 2
• 239000000203 mixture Substances 0.000 claims 2
• 241000712461 unidentified influenza virus Species 0.000 claims 2
• 241000713869 Moloney murine leukemia virus Species 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 238000006664 bond formation reaction Methods 0.000 claims 1
• 230000002401 inhibitory effect Effects 0.000 claims 1
• 208000032839 leukemia Diseases 0.000 claims 1
• 108010091748 peptide A Proteins 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• 239000002243 precursor Substances 0.000 claims 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
• 230000002194 synthesizing effect Effects 0.000 claims 1